Summary
The importance of steroid receptors for the prognosis of mammary carcinoma has been evaluated by investigating the course of disease in 163 patients for a median follow up time of 66 months after mastectomy. Multivariate analysis including estrogen receptor (ER), progesterone receptor (PgR), the presence of 8S and 4S ER together or 4S ER only, and the lymph node status revealed only the latter to have significant (p<0.001) predictive potency. Lymph node positive (N-pos) patients had a 3.3 (1.7–6.2) fold risk of death and 2.8 (1.7–4.7) fold risk of recurrence relative to node negative (N-neg) patients.
When we compared overall survival (OAS) and disease-free survival (DFS) in the various receptorpositive groups with the groups that displayed neither ER nor PgR, significant differences in prognosis were only seen in N-neg patients. PgR did not turn out to be a better prognostic factor than ER, nor was the 8S ER a sing of increased OAS and DFS compared to total ER. However, the number of patients in this group was too small to allow a definite statement.
References
Knight WA, Livingston RB, Gregory BJ, McGuire WL: Recurrence in breast cancer. Cancer 37: 4669–4671, 1977
Hähnel R, Woodings T, Vivian AB: Prognostic value of estrogen receptor in primary breast cancer. Cancer 44: 671–675, 1979
Reiner G, Jakesz R, Kolb R, Bettelheim P, Bieglmayer C, Spona J: Prognostic value of estrogen receptors in breast cancer. Chir Forum Exp Klin Forsch: 315-318, 1980
Hartveit F, Maartmann-Moe H, Stoa KF, Tangen M, Thorsen T: Early recurrence in estrogen receptor negative breast carcinomas. A preliminary report. Acta Chir Scand 146: 93–95, 1980
Croton R, Cooke T, Holt S, George WD, Nicolson R, Griffiths K: Estrogen receptors and survival in early breast cancer. Br Med J (Clin Res) 283: 1289–1291, 1981
Kinne DW, Ashikari R, Butler A, Menendez-Botet C, Rosen PP, Schwartz M: Estrogen receptor protein in breast cancer as a predictor of recurrence. Cancer 47: 2364–2367, 1981
Blamey RW, Bishop HM, Blake JR, Doyle PJ, Elston CW, Haybittle JL, Nicholson RI, Griffiths K: Relationship between primary breast tumor receptor status and patient survival. Cancer 46: 2765–2769, 1980
Crowe JP, Hubay CA, Pearson OH, Marshall JS, Rosenblatt HJ, Mansour EG, Hermann RE, Jones JC, Flynn WJ, McGuire WL: Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res Treat 2: 171–176, 1982
Heise E, Gorlich M: Estradiol receptor activity in human breast cancer, disease free interval and survival time. Anticancer Res 2: 33–36, 1982
Mason BH, Holdaway IM, Mullins PR, Yee LH, Kay RG: Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res 43: 2985–2990, 1983
Mercer RJ, Bryan RM, Bennett RC, Rennie GC, Lie TH, Morgan FJ: The prognostic value of estrogen receptor in breast cancer. Aust NZ J Surg 54: 7–10, 1984
Blanco G, Alavaikko M, Ojala A, Collan Y, Heikkinen M, Hietanen T, Aine R, Taskinen PJ: Estrogen and progesterone receptors in breast cancer: Relationships to tumour histopathology and survival of patients. Anticancer Res 4: 383–389, 1984
Allegra JC, Lippman ME, Simon R, Thompson EB, Barlock A, Green L, Huff KK, Do HMT, Aitken SC, Warren R: Association between steroid hormone receptor status and disease free interval in breast cancer. Cancer Treat Rep 63: 1271–1277, 1979
Furmanski P, Saunders DE, Brooks SC, Rich MA: The prognostic value of estrogen receptor determinations in patients with primary breast cancer: An update. Cancer 46: 2794–2796, 1980
Adami HO, Graffman S, Lindgren A, Sallstrom J: Prognostic implication of estrogen receptor content in breast cancer. Breast Cancer Res Treat 5: 293–300, 1985
von Maillot K, Horke W, Prestele H: Prognostic significance of the steroid receptor content in primary breast cancer. Arch Gynecol 231: 185–190, 1982
Shapiro CM, Schifeling D, Bitran JD, Desser RK, Rochman H, Michel A, Shapiro R, Evans R, Kozloff MF, Recant W, Billings AA: Prognostic value of the estrogen receptor level in pathologic stage I and II adenocarcinoma of the breast. J Surg Oncol 19: 119–121, 1982
Howat JM, Barnes DM, Harris M, Swindell R: The association of cytosol estrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease. Br J Cancer 47: 629–640, 1983
Aamdal S, Bormer O, Jorgensen O, Host H, Eliassen G, Kaalhus O, Pihl A: Estrogen receptors and long-term prognosis in breast cancer. Cancer 53: 2525–2529, 1984
Howell A, Barnes DM, Harland RN, Redford J, Bramwell VH, Wilkinson MJ, Swindell R, Crowther D, Sellwood RA: Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet 1: 588–591, 1984
Saez S, Cheix F, Asselain B: Prognostic value of estrogen and progesterone receptors in primary breast cancer. Breast Cancer Res Treat 3: 345, 1983
Ciatto S, Bravetti P, Cardona G, Cataliotti L, Crascioli R, Herd-Smith A, Messeri G: Prognostic role of estrogen receptor determination in breast cancer. Tumori 69: 527–530, 1983
Butler JA, Bretsky S, Menendez-Botet C, Kinne DW: Estrogen receptor protein of breast cancer as a predictor of recurrence. Cancer 55: 1178–1181, 1985
Alanko A, Heimonen E, Scheinin TM, Tolppanen EM, Vikko R: Oestrogen and progesterone receptors and disease-free interval in primary breast cancer. Br J Cancer 50: 667–672, 1984
Parl FF, Schmidt BP, Dupont WD, Wagner RK: Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer 54: 2237–2242, 1984
Hilf R, Feldstein ML, Gibson SL, Savlov ED: Does estrogen receptor status have prognostic value for recurrence or chemotherapy response of breast cancer? Proc Amer Assoc Cancer Res 20: 298–302, 1979
Stewart JF, Rubens RD, Millis RR, King RJ, Hayward JL: Steroid receptors and prognosis in operable (stage I and II) breast cancer. Eur J Cancer Clin Oncol 19: 1381–1387, 1983
Howat JM, Harris M, Swindell R, Barnes DM: The effect of estrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast. Br J Cancer 51: 263–270, 1985
Samaan NA, Buzdar AU, Aldinger KA, Schultz PN, Yang KP, Romsdahl MM, Martin R: Estrogen receptor: A prognostic factor in breast cancer. Cancer 57: 554–560, 1981
Clark GM, McGuire WL: Progesterone receptors and human breast cancer. Breast Cancer Res Treat 3: 157–166, 1983
Korenmann SG, Dukes BA: Specific estrogen binding by the cytoplasm of human breast carcinoma. J Clin Endocrinol Metab 30: 639–645, 1970
Wittliff JL, Hilf R, Brooks WF Jr, Savlov ED, Hall TC, Orlando RA: Specific estrogen binding capacity of the cytoplasmatic receptor in normal and neoplastic tissue. Cancer Res 32: 1983–1992, 1972
Wilcoxon F: Individual comparison by ranking methods. Biometrics 1: 80–83, 1945
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 35: 1–39, 1977
Cox DR: Regression models and life tables (with discussion). J R Stat Soc 34: 187–220, 1972
Wittliff JL: Steroid-hormone receptors in breast cancer. Cancer 53: 630–643, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Daxenbichler, G., Forsthuber, EP., Marth, C. et al. Steroid hormone receptors and prognosis in breast cancer. Breast Cancer Res Tr 12, 267–273 (1988). https://doi.org/10.1007/BF01811239
Issue Date:
DOI: https://doi.org/10.1007/BF01811239